Hepatitis C virus replicons: dinosaurs still in business?

I. Woerz, V. Lohmann and R. Bartenschlager  
Department of Molecular Virology, University of Heidelberg, Heidelberg, Germany

Received September 2008; accepted for publication September 2008

SUMMARY. Since the molecular cloning of the hepatitis C virus (HCV) genome for the first time in 1989, there has been tremendous progress in our understanding of the multiple facets of the replication cycle of this virus. Key to this progress has been the development of systems to propagate the virus in cell culture, which turned out to be a notoriously difficult task. A major breakthrough has been the construction of subgenomic replicons that self-amplify in cultured human hepatoma cells. These RNAs recapitulate the intracellular steps of the HCV replication cycle and have been instrumental to decipher details of the RNA amplification steps including the identification of key host cell factors. However, reproduction of the complete viral replication cycle only became possible with the advent of a particular molecular HCV clone designated JFH-1 that replicates to very high levels and supports the production of infectious virus particles. The availability of this new culture system raises the question, whether the use of replicons is still justified. In this review, we will discuss the pros and cons of both systems.

Keywords: HCV cell culture system, HCVcc, hepatitis C virus, replicon system.

INTRODUCTION

The hepatitis C virus (HCV) is an enveloped positive-strand RNA virus of the genus Hepacivirus within the family Flaviviridae [1]. Primary infections with HCV are often asymptomatic or associated with only mild symptoms, but they mostly become persistent causing chronic liver disease [2,3], which may lead to liver cirrhosis and hepatocellular carcinoma. At present, more than 170 million people suffer from chronic hepatitis C [4] making HCV infection a global health problem. Current treatment consists of a combination of polyethylene glycol-conjugated interferon-alpha and ribavirin [4], but patients have to endure serious side effects (reviewed in Ref. [5]). In addition, success rates are limited and the outcome of therapy very much depends on the genotype of the infecting virus [6].

After the first molecular cloning of the HCV genome in 1989 [7], the development of specific antiviral therapies appeared to be within reach. However, progress in drug development was slowed down very much by the lack of systems to propagate HCV in cell culture (HCVcc). Hopes to establish such systems were high with the construction of infectious molecular HCV clones [8,9], but their replication competence demonstrated in experimentally inoculated animals could not be confirmed in cultured cells (reviewed in Ref. [10], see Table 1).

HCV REPLICONS OF THE FIRST GENERATION

A major step forward towards establishment of a robust and reliable cell culture system for HCV was therefore the development of subgenomic and selectable HCV replicons [11]. By definition, a replicon is a nucleic acid (which can be DNA or RNA) that is capable of autonomous replication. In this sense, the HCV genome itself can be regarded as a replicon. However, for clarity, in this review, we refer to replicons as RNA molecules capable only of intracellular self-replication, i.e. unable to support the production of infectious HCV particles.

Key to the establishment of the HCV replicon system was a molecularly cloned full length genome, designated Con1. In which the region encoding for the protein core to nonstructural protein 2 (NS2) or p7 was replaced by two
nonviral elements: first, the neomycin phosphotransferase (neo) gene that allows to select for resistance against the drug G418 and second, the internal ribosome entry site (IRES) from a picornavirus (Fig. 1A a,b,c). The resulting construct was bicistronic with the first cistron encoding the neo gene and the second, the HCV replicase genes (NS3–NS5B). Upon transfection of the human hepatoma cell line Huh-7 with in vitro transcripts derived from the cloned replicon cDNA and subsequent G418 treatment, it became possible to select for a few G418-resistant colonies that supported HCV RNA replication to unexpectedly high levels (1000–5000 positive-strand RNA molecules per cell). Replication of these RNAs was resistant against actinomycin D which blocks DNA-dependent, but not RNA-dependent RNA synthesis thus providing formal proof that the HCV replicons indeed replicated autonomously in these cells.

Subsequent to the establishment of Con1 replicons, the same approach was used to generate replicons of other HCV isolates and nowadays replicons derived from more than eight isolates and covering genotypes 1a, 1b and 2a are available (Table 1).

### IMPROVEMENTS OF THE REPLICON SYSTEM

Further studies identified two major prerequisites for efficient replication of these HCV replicons: first, the selection for replication-enhancing (cell culture adaptive) mutations; second, the selection for particular Huh-7 cells that are highly permissive for HCV RNA replication [12]. Adaptive mutations were found to cluster in four distinct regions of the HCV polyprotein: in the N-terminus of the NS3 helicase, at two positions in NS4B and in the centre of NS5A. Recloning of these mutations into the parental replicon resulted in a strong increase in RNA replication efficiency with the degree of enhancement depending on the particular mutation or combination of mutations [13–15]. Interestingly, adaptive mutations may also be selected for directly in cell culture [16].

### Table 1 In vivo and in vitro replicative capacity of some molecular HCV clones (adapted from Ref. [81])

| HCV isolate       | In vivo study | RNA replication (replicon) | Cell culture study |
|-------------------|---------------|---------------------------|--------------------|
|                   | Infectivity*  | References                | Production of infectious virus | References |
| H77               | 1a            | +                         | (requires adaptive mutations) | n.r.       |
| H77C              | 1a            | +                         | (requires adaptive mutations) | n.r.       |
| HCV-1             | 1a            | +                         | (requires adaptive mutations) | n.r.       |
| BK                | 1b/1a 3’end   | +                         | (requires adaptive mutations) | n.r.       |
| HC-J4             | 1b ORF/1a 3’NTRs    | +                         | (requires adaptive mutations) | n.r.       |
| HCV-N             | 1b            | ±                         | (insertion in NS5A confers adaptation) | ±(transient assay wt Con1) |
| HCV-CG1b          | 1b            | +                       | (DNA-expression system) | ±(DNA-expression system) |
| Con1              | 1b            | +                         | (more efficient with adaptive mutations) | ±(transient assay wt Con1) |
|                   |               |                           |                    | (adapted Con1) |
| HC-J6(CH)         | 2a            | +                         | (more efficient with adaptive mutations) | n.r.       |
| JFH-1             | 2a            | +                       | ++                  | + (more efficient with adaptive mutations) |
| JFH-1 based chimeras | See Fig. 1B 1B a | +                       | ++                  | ++ (J6-JFH-1), + (Con1-JFH-1), ±(H77-JFH-1), ±(452-JFH-1) |

n.r., not reported. *Infectivity was tested by inoculation of in vitro transcripts into the liver of chimpanzees or mice with human liver xenografts with cell culture grown HCV. †Chimeric HCV genomes. ‡Only cell culture grown virus was tested for infectivity.
systems. For instance, reporter replicons containing the adaptive mutations greatly broadened the scope of HCVcc clones are Huh7.5 and Huh7-Lunet [16,18].

The availability of highly permissive cell clones and adaptive mutations greatly broadened the scope of HCVcc systems. For instance, reporter replicons containing the luciferase gene and applicable for transient (short-term) assays became available (Fig. 1A d) [13,14]. In addition, cell lines containing stably replicating reporter replicons were generated that are well applicable for high-throughput screening purposes (Fig. 1A e) (reviewed in Ref. [19]). Monocistronic replicons were constructed as well, containing only the HCV IRES and thereby closely mimicking the translational properties of authentic viral genomes (Fig. 1A f) [20]. Moreover, it became possible to generate stable cell clones carrying self-replicating genomic replicons expressing all viral proteins [16,21–23]. However, attempts to demonstrate HCV particles released into the culture supernatant of these cells failed. This is due to the fact that cell culture adaptive mutations interfere with the production of infectious virus particles (T. Pietschmann and R. Bartenschlager, unpublished results). In line with this observation, a Con1 genome containing such adaptive mutations was unable to
establish productive infection in vivo whereas chimpanzees inoculated with the wild type Con1 genome were readily infected [24].

THE INFECTIOUS VIRUS SYSTEM (HCVcc)

Inspite of great progress with HCV replicons, the lack of virus production was an obvious limitation of this system. Because of the assembly block imposed by adaptive mutations on one hand, and the very low (most often nondetectable) replication of nonadapted replicons on the other hand, a full-cycle culture system only became possible with the identification of an HCV isolate that was capable of high-level replication without requiring cell culture-adaptive mutations. This ‘holy grail’ was discovered by Kato et al. [25], who cloned a genotype 2a consensus genome designated JFH-1 from a Japanese patient with fulminant hepatitis. For reasons still not understood, replicons derived from this isolate replicate to exceptionally high levels without requiring adaptive mutations [26]. Most importantly, transfection of JFH-1 full-length genomes into Huh-7 cells supports the production of virus particles that are infectious in cell culture and inoculated animals (chimpanzee and transgenic mice with human liver xenografts), confirming that cell culture-derived HCV particles (designated HCVcc) represent authentic virions [27–29].

IMPROVEMENTS OF THE HCVcc SYSTEM

In the light of the rather low infectivity titres attained with JFH-1 [about 10⁴ tissue culture infectious dose 50 (TCID₅₀) per mL], much effort was made to improve the system. One major progress was the generation of virus chimeras consisting essentially of the JFH-1 replicase (NS3–NS5B) fused to the core to NS2 region of other HCV isolates (Fig. 1B a). Lindenbach et al. [30] described a chimera consisting of the structural region of a genotype 2a isolate [J6 (CF)] fused to the JFH-1 replicase. Pietschmann and colleagues identified a more efficient fusion site (designated ‘C3’) and enlarged the panel of virus chimeras to the isolates Con1 (gt 1b), H77 (gt 1a), 452 (gt 3a) and J6 (gt 2a) (Fig.1B a). Virus titres of the most efficient intragenotypic chimera that was designated Jc1 are in the range of 10⁶ TCID₅₀/mL [31], i.e. about 100-fold higher compared with JFH-1.

Alternative to virus chimeras, cell culture adaptation of JFH-1 by continuous passage of persistently infected cells allowed the construction of highly efficient JFH-1 variants that also support virus production to much higher levels as compared with the parental JFH-1 [29,32–35]. Finally, the identification of proper Huh-7 cell clones was again a key for a robust HCVcc system as it was for the replicons. Two notable examples are Huh7.5 and Huh7-Lunet/CD81 high. The latter are derived from Huh7-Lunet cells by stable overexpression of CD81, which is required for efficient infection [36]. Recently, a novel human hepatoma cell line, LH86, was shown to be susceptible to HCV infection and supporting HCV RNA replication [37].

In analogy to HCV replicons, JFH-1 derived virus genomes with insertions of reporter genes have been described (Fig.1B b,c) [28,38,39]. Moreover, genomes with a stably inserted gene encoding for the green fluorescent protein were generated allowing the live visualization of HCV infected cells [40] (Fig. 1B d).

OTHER CELL-BASED HCV SYSTEMS

Amongst the other available model systems to study HCVcc, the pseudoparticle system (HCVpp) is perhaps the most important one [41,42] (Fig. 2). HCVpps are retroviral nucleocapsids surrounded by a lipid envelope that contains authentic HCV glycoprotein complexes. As the early steps of the viral replication cycle are driven by the envelope proteins largely independent from the other structural proteins, HCVpp is an ideal system to study receptor binding and entry and has been used intensively to characterize neutralizing antibodies.

Very recently, Steinmann et al. [43] described the production of HCV-like particles (referred to as HCV TCP) that are composed of authentic virus particles that contain a subgenomic RNA. Upon infection of Huh-7 cells, these RNAs...
replicate to high levels, yet do not produce infectious progeny because of the deletion of the structural genes. This system is also well suited to study the early and late steps of infection, but does not require a biosafety level 3 laboratory as is the case for full-length HCV sequences.

Another system to study the HCV replication cycle in a more authentic setting is the infection of primary human hepatocytes (PHH). Successful infection could be demonstrated with serum- and cell culture-derived HCV particles [44, 45]. However, preparation of PHH is a time-consuming and laborious process, the quality of PHH is difficult to control and genome replication of JFH-1 viruses is about 1 order of magnitude lower in PHH compared with Huh-7.5 cells [45].

Prior to the establishment of HCV replicons, surrogate models have been used, in particular, the pestivirus bovine viral diarrhoea virus (BVDV) that shares many features with HCV such as the genome organization and the overall replication cycle. As BVDV can easily be cultured in vitro, it has been a promising model system (reviewed in Ref. [46]). An additional surrogate model is based on GB virus B (GBV-B), one of the closest genetic relatives to HCV within the Flaviviridae family. GBV-B replicons have been constructed that are similar to those developed for HCV, but propagation of infectious GBV-B is also only possible in primary cell cultures (reviewed in Ref. [47]).

THE PROS AND CONS OF THE HCV REPLICON AND THE HCVcc SYSTEM

With the plethora of cell-based HCV replication systems developed in the past few years, most notably the HCVcc system, the question arises as to which role replicons will play in the future both in basic and applied research. At a first glance, the HCVcc system is superior because it covers the complete viral replication cycle (Fig. 2). However, the early steps (virus binding, entry, uncoating) can already be addressed with the HCVpp system (Fig. 2). In fact, most, if not all observations made with the HCVpp system have been confirmed by using cell culture grown HCV particles. For instance, CD81 and scavenger receptor B class I have been validated as important entry molecules (reviewed in Ref. [48]). Moreover, the essential role of claudin-1 in HCV entry was recently identified by using HCVpp and verified by HCVcc [49]. Finally, HCV entry via a low pH-dependent step originally described with HCVpp has now been confirmed with HCVcc [39, 42, 50]. Nevertheless, because of the higher authenticity, most future studies will analyse HCV infection primarily by using cell culture grown HCV. Moreover, when using a highly assembly competent HCV variant, the production of high titre HCVcc stocks is easier compared with HCVpp stocks, which cannot be passaged but rather must be generated by repeated RNA transfection.

When considering RNA replication (Fig. 2), results obtained with the HCVcc system or the replicon system will likely be the same. For instance, the important role of lipids for RNA replication observed with subgenomic replicons has been confirmed in the HCVcc system [51, 52]. Likewise, the dependence of HCV replication on cyclophilins was found both in the replicon system and with HCVcc [53–55]. Depending on the particular question, one system may be superior over the other. For instance, when performing knock-down experiments of a particular host cell factor, the impact of the knock-down often is easier to detect in an infection-based system rather than in the replicon system. This is due to the fact that upon infection, only few virus genomes enter the cell, especially when using a low multiplicity of infection. In this setting, a limiting host cell factor will impose a much higher barrier to RNA amplification compared with cells with a stable replicon where the RNA copy number is already high and where stable replication complexes have already been formed. Still, replicons will remain indispensable to analyse the mechanistic roles of host factors, NS proteins and cis-acting elements in RNA replication compared with other stages of the viral life cycle.

Probably, the strongest impact the HCVcc system has deals with the late steps of the replication cycle, i.e. assembly and release. These aspects could not be addressed properly by any of the surrogate systems. Although the formation of virus-like particles had been described in insect cells upon infection with recombinant baculoviruses or in mammalian cells upon transfection with alphavirus vectors directing the expression of the HCV structural genes, none of these systems adequately reflects authentic HCV assembly [56, 57]. This is best illustrated by the fact that in none of these systems, virus (-like) particles were secreted. In contrast, infectious particles are readily assembled in the HCVcc system and some variants support high titres. Taking advantage of that system, it soon became clear that HCV particles assemble in close proximity of the surface of lipid droplets where the majority of core protein accumulates [58–60]. Infectious virus particles appear to acquire their envelope by budding into the lumen of the endoplasmic reticulum in close apposition to lipid droplets and are released from the cell in close association with the very-low-density lipoprotein pathway [61].

Apart from these insights into the peculiarities of HCV assembly, the possibility to produce infectious virus particles in the laboratory under well-defined conditions opens new avenues to visualize infectious HCV. In this respect, there is no alternative to the HCVcc system. However, increasing evidence points to important roles of HCV NS proteins, particularly NS5A, in viral assembly and subgenomic replicons will remain valuable tools to dissect the different functions of these proteins [33, 62–64].

The major limitation of the HCVcc system is its restriction to a single isolate (JFH-1) that supports efficient virus production. Although, production of infectious particles has also been described for a highly adapted H77 (genotype 1a) isolate, virus titres attained with this genome and infectivity of released particles appear to be very low [65]. In that respect, HCV replicons cover a broader range of isolates and...
genotypes (Table 1), particularly of genotype 1, which is most common worldwide. The availability of such a spectrum of systems is probably most important for the development of antiviral drugs. In fact, subgenomic HCV replicons contain the prime drug targets: the NS3 protease and the NS5B RdRp. Moreover, replicons are more amenable for genetic manipulation such as the construction of chimeras in which the protease or polymerase gene is replaced by the corresponding gene from another HCV isolate or even from genomes isolated from an infected patient. In contrast, work in our laboratory has shown that replacing, e.g. the NS3 protease gene of JFH-1 by the one of another functional HCV clone in all cases very much reduced or completely abolished virus assembly (A. Kaul, A.L. Gamer and R. Bartenschlager, unpublished results). Likewise, as the NS5B gene of JFH-1 appears to be a major determinant for efficient RNA replication, replacements by NS5B genes from other HCV isolates are very difficult [20,66]. In contrast, such replacements have been described for subgenomic replicons derived, e.g. from Con1 and utilized to established phenotypic resistance assays [67,68].

Because of the high ‘genetic flexibility’ of replicons, they can be designed with much more ease as compared with full length virus genomes. For instance, selectable replicons with a stably expressed reporter gene (Fig. 1A e) have been used for high throughput drug screening purposes (reviewed in Ref. [19]). Because of the easy read-out and the robust signal, such assays can be automated and adjusted to robotics, which is important not only for drug screening but also for screening of large-scale small interfering RNA libraries in search for host cell factors required for HCV replication [69,70]. Moreover, replicons do not impose a biohazard allowing screening purposes under the lowest biosafety levels, which is not possible when working with the HCVcc system. In case of the latter, a high throughput screen will also require the prior large-scale production of infectious virus stocks, which may be challenging even when using highly assembly competent variants such as Jc1.

Hepatitis C virus replicons have also been very instrumental to select for antiviral drug resistance. In most cases, selectable replicons have been used in which the selection marker (e.g. G418 for neo replicons) is exploited to preserve the replicon in the face of selective pressure imposed by an antiviral compound, resulting in the selection of cell clones with conserved mutations in the viral RNA. In contrast, when using the HCVcc system, this is not really possible because a strong antiviral compound with a high genetic barrier will rapidly eliminate the virus from the culture (A. Kaul and R. Bartenschlager, unpublished results). Furthermore, if mutations at independent positions confer resistance, it will be hard to identify relevant mutations in the viral quasispecies. Although the construction of bicistronic selectable JFH-1 genomes that support the production of infectious virus particles is possible [71], replication of such genomes is extremely impaired and virus titres are very low. Therefore, such genomes will be rapidly lost when passaging cells in the presence of an antiviral compound (A. Kaul and R. Bartenschlager, unpublished results).

Possible limitations originally described for HCV replicons are the restriction to HuH-7 cells and the dependence on host cell growth. With respect to cell lines, stable replication (by using selectable replicons) has now been achieved for a number of other cell lines such as human hepatoma cells (HuH6 or LH86 [37,72]), human nonliver cells (HeLa or 293 [73–75]), nonhuman liver cells (Hepal–6 [75]) and nonhuman nonliver cells (mouse embryonic fibroblasts [76]). Moreover, the inhibition of HCV replication that was observed in confluent nondividing HuH-7 cells has not been found in HuH6 [72] and HeLa [77] cells. The underlying reasons are not quite clear, but may be because of limiting nucleoside triphosphate pools in resting HuH-7 cells [78]. It should be pointed out that the same observations have been made when using JFH-1 derived replicons and the full length genome. In fact, virus production also ceases in confluent HuH-7 cells and efficient replication and spread is largely restricted to particular HuH-7 cell clones. Thus, these limitations are no peculiarities of certain replicons, but rather reflect some properties of HCV replication in certain host cells.

PERSPECTIVES

There is no doubt that the possibility to produce recombinant infectious HCV particles in the laboratory opens new avenues to study the viral replication cycle. The early and late steps can now be targeted by inhibitors of virus binding and fusion [79] or assembly and release [80]. The construction of virus chimeras composed of the JFH-1 replicase and the structural region of other isolates has broadened the scope of the HCVcc system, which is particularly helpful when studying neutralizing antibodies [28]. However, a major limitation is the restriction to a single genotype 2a isolate, which from a drug development point of view is least interesting because of the rather high sustained viral response rates to current therapy of patients infected with genotype 2 viruses. Construction of replicase chimeras so far were of limited success and further studies will be required to overcome that hurdle and to identify novel molecular HCV clones replicating to high level in cell culture and supporting the production of infectious particles. At least until then, but most probably beyond this time point, the replicon system will be a valuable and important tool for basic and applied research.

ACKNOWLEDGEMENTS AND DISCLOSURES

We are grateful to Darius Moradpour for providing the basic scheme of Fig. 2.

Work in the author’s laboratory was supported by grants from the Landesstiftung Baden-Württemberg (P-LS-RNS30) and a grant from the VIRGIL European Network of Excellence (LSHM-CT-2004-503359).
REFERENCES

1 Van Regenmortel MHV, Fauquet CM, Bishop DHL et al. Virus Taxonomy: The VIth Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press, 2000.

2 Hoofnagle JH. Course and outcome of hepatitis C. HEPATOLOGY 2002; 36: 821–829.

3 Sceff LJ. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36: 835–846.

4 Poynard T, Yuen MF, Rutziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095–2100.

5 Cross TJ, Antoniades CG, Harrison PM. Current and future management of chronic hepatitis C infection. Postgrad Med J 2008; 84: 172–176.

6 Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121–S127.

7 Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–362.

8 Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C virus by intrahepatic inoculation with transcribed RNA. Science 1997; 277: 570–574.

9 Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfectioned into the liver of a chimpanzee. Proc Natl Acad Sci U S A 1997; 94: 8738–8743.

10 Bartenschlager R. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Curr Opin Microbiol 2006; 9: 416–422.

11 Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110–113.

12 Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004; 63: 71–180.

13 Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture – adaptive mutations. J Virol 2001; 75: 4614–4624.

14 Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 2003; 77: 3007–3019.

15 Lohmann V, Körner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNA conferring cell culture adaptation. J Virol 2001; 75: 1437–1449.

16 Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76: 13001–13014.

17 Murray EM, Grobler JA, Markel EF et al. Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells. J Virol 2003; 77: 2928–2935.

18 Friebe P, Boudet J, Simorre JP, Bartenschlager R. Kissing-loop interaction in the 3′ end of the hepatitis C virus genome essential for RNA replication. J Virol 2005; 79: 380–392.

19 Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov 2002; 1: 911–916.

20 Binder M, Quinkert D, Bohchkarova O et al. Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol 2007; 81: 5270–5283.

21 Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003; 77: 3181–3190.

22 Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002; 76: 2997–3006.

23 Pietschmann T, Lohmann V, Kaul A et al. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 2002; 76: 4008–4021.

24 Bukh J, Pietschmann T, Lohmann V et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A 2002; 99: 14416–14421.

25 Kato T, Furusaka A, Miyamoto M et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001; 64: 334–339.

26 Kato T, Date T, Miyamoto M et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003; 125: 1808–1817.

27 Lindenbach BD, Meuleman P, Ploss A et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 2006; 103: 3805–3809.

28 Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791–796.

29 Zhong J, Gastaminza P, Cheng G et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 9294–9299.

30 Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623–626.

31 Pietschmann T, Kaul A, Koutsoudakis G et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006; 103: 7408–7413.

32 Gottwein JM, Scheel TK, Hoegh AM et al. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 2007; 133: 1614–1626.

33 Kaul A, Woerz I, Meuleman P, Leroux-Roels G, Bartenschlager R. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol 2007; 81: 13168–13179.

34 Scheel TK, Gottwein JM, Jensen TB et al. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A 2008; 105: 997–1002.

35 Yi M, Ma Y, Yates J, Lemon SM. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-
infectious intergenotypic chimeric hepatitis C virus. *J Virol* 2007; 81: 629–638.

36 Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. *J Virol* 2007; 81: 588–598.

37 Zhu H, Dong H, Eksioglu E et al. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. *Gastroenterology* 2007; 133: 1649–1659.

38 Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. *J Virol* 2007; 81: 8374–8383.

39 Koutsoudakis G, Kaul A, Steinmann E et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. *J Virol* 2006; 80: 5308–5320.

40 Schaller T, Appel N, Koutsoudakis G et al. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. *J Virol* 2007; 81: 4591–4603.

41 Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. *J Exp Med* 2003; 197: 633–642.

42 Hsu M, Zhang J, Flint M et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. *Proc Natl Acad Sci U S A* 2003; 100: 7271–7276.

43 Steinmann E, Brohm C, Kallis S, Bartenschlager R, Pietschmann T. Efficient trans-encapsulation of hepatitis C virus RNAs into infectious virus-like particles. *J Virol* 2008; 82: 7034–7046.

44 Fournier C, Sureau C, Coste J et al. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. *J Gen Virol* 1998; 79: 2367–2374.

45 Molina S, Castet V, Pichard-Garcia L et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. *J Virol* 2008; 82: 569–574.

46 Buckwold VE, Beer BE, Donis RO. Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. *Antiviral Res* 2003; 60: 1–15.

47 Beames B, Chavez D, Lanford RE, GB virus B as a model for hepatitis C virus. *ILAR J* 2001; 42: 152–160.

48 Helle F, Dubuisson J. Hepatitis C virus entry into host cells. *Cell Mol Life Sci* 2008; 65: 100–112.

49 Evans MJ, von Hahn T, Tscherner DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature* 2007; 446: 801–805.

50 Tscherner DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. *J Virol* 2006; 80: 1734–1741.

51 Huang H, Chen Y, Ye J. Inhibition of hepatitis C virus replication by peroxidation of arachidionate and restoration by vitamin E. *Proc Natl Acad Sci U S A* 2007; 104: 18666–18670.

52 Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. *Proc Natl Acad Sci U S A* 2003; 100: 15865–15870.

53 Paeshuys J, Vliegen I, Coemont L et al. Comparative in vitro anti-hepatitis C virus activity of a selected series of polymerase, protease and helicase inhibitors. *Antimicrob Agents Chemother* 2008; 52: 3433–3437.

54 Robida JM, Nelson HB, Liu Z, Tang H. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. *J Virol* 2007; 81: 5829–5840.

55 Yang F, Robotham JM, Nelson HB, Insigler A, Kenworthy R, Tang H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. *J Virol* 2008; 82: 5269–5278.

56 Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. *J Virol* 1998; 72: 3827–3836.

57 Blanchard E, Brand D, Trassard S, Goudeau A, Roingeard P. Hepatitis C virus-like particle morphogenesis. *J Virol* 2002; 76: 4073–4079.

58 Boulant S, Targett-Adams P, McLauchlan J. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. *J Gen Virol* 2007; 88: 2204–2213.

59 Miyaniy Y, Atsuwaza K, Usuda N et al. The lipid droplet is an important organelle for hepatitis C virus production. *Nat Cell Biol* 2007; 9: 1089–1097.

60 Shuvinskaya A, Boulant S, Penin F, McLauchlan J, Bartenschlager R. The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly. *J Biol Chem* 2007; 282: 37158–37169.

61 Huang H, Sun F, Owen DM et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. *Proc Natl Acad Sci U S A* 2007; 104: 5848–5853.

62 Appel N, Zayas M, Miller S et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. *PLoS Pathog* 2008; 4: e1000035.

63 Masaki T, Suzuki R, Murakami K et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. *J Virol* 2008; 82: 7964–7976.

64 Tellinghusen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. *PLoS Pathog* 2008; 4: e1000032.

65 Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. Production of infectious genotype 1a hepatitis C virus infectious particle. *J Virol* 2007; 81: 7964–7976.

66 Murayama A, Date T, Morikawa K et al. The NS3 helicase and NS5B-3′X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells. *J Virol* 2007; 81: 8030–8040.

67 Le Pogam S, Seshaudri A, Kosaka A et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. *J Antimicrob Chemother* 2008; 61: 1205–1216.

68 Middleton T, He Y, Pilot-Matias T et al. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. *J Virol Methods* 2007; 143: 137–145.
Hepatitis C virus replicon system

9

59 Ng TI, Mo H, Pilot-Matias T et al. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 2007; 45: 1413–1421.

60 Supekova L, Supek F, Lee J et al. Identification of human kinases involved in HCV replication by siRNA library screening. J Biol Chem 2007; 282: 29–36.

61 Date T, Miyamoto M, Kato T et al. An infectious and selectable full-length replicon system with hepatitis C virus JFH-1 strain. Hepatol Res 2007; 37: 433–443.

62 Windisch MP, Frese M, Kaul A, Trippler M, Lohmann V, Bartenschlager R. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J Virol 2005; 79: 13778–13793.

63 Ali S, Pellerin C, Lamarre D, Kukolj G. Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. J Virol 2004; 78: 491–501.

64 Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, Wakita T. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 2005; 79: 592–596.

65 Zhu Q, Guo JT, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 2003; 77: 9204–9210.

66 Chang KS, Cai Z, Zhang C, Sen GC, Williams BR, Luo G. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol 2006; 80: 7364–7374.

67 Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75: 8516–8523.

68 Stuyver LJ, McBrayer TR, Tharnish PM et al. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J Virol 2003; 77: 10689–10694.

69 Van Compernolle SE, Wiznycia AV, Rush JR, Dhanasekaran M, Baures PW, Todd SC. Small molecule inhibition of hepatitis C virus E2 binding to CD81. Virology 2003; 314: 371–380.

70 Steinmann E, Whitfield T, Kallis S et al. Antiviral effects of amantadine and aminosugar derivatives against hepatitis C virus. Hepatology 2007; 46: 330–338.

71 Bartenschlager R, Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res 2007; 127: 195–207.

72 Windisch MP, Frese M, Kaul A, Trippler M, Lohmann V, Bartenschlager R. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J Virol 2005; 79: 13778–13793.

73 Ali S, Pellerin C, Lamarre D, Kukolj G. Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. J Virol 2004; 78: 491–501.

74 Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, Wakita T. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 2005; 79: 592–596.

75 Zhu Q, Guo JT, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 2003; 77: 9204–9210.

76 Chang KS, Cai Z, Zhang C, Sen GC, Williams BR, Luo G. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol 2006; 80: 7364–7374.

77 Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75: 8516–8523.

78 Stuyver LJ, McBrayer TR, Tharnish PM et al. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J Virol 2003; 77: 10689–10694.

79 Van Compernolle SE, Wiznycia AV, Rush JR, Dhanasekaran M, Baures PW, Todd SC. Small molecule inhibition of hepatitis C virus E2 binding to CD81. Virology 2003; 314: 371–380.

80 Steinmann E, Whitfield T, Kallis S et al. Antiviral effects of amantadine and aminosugar derivatives against hepatitis C virus. Hepatology 2007; 46: 330–338.

81 Bartenschlager R, Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res 2007; 127: 195–207.

82 Yi M, Lemon SM. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J Virol 2004; 78: 7904–7915.

83 Lanford RE, Lee H, Chavez D, Guerra B, Brasky KM. Infectious cDNA clone of the hepatitis C virus genotype 1 prototype sequence. J Gen Virol 2001; 82: 1291–1297.

84 Lanford RE, Guerra B, Lee H et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003; 77: 1092–1104.

85 Grobler JA, Markel EJ, Fay JF et al. Identification of a key determinant of hepatitis C virus cell culture adaptation in domains II of NS3 helicase. J Biol Chem 2003; 278: 16741–16746.

86 St Yanagi M, Shapiro M, Emerson SU, Purcell RH, Bukh J. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 1998; 244: 161–172.

87 Maekawa S, Enomoto N, Sakamoto N et al. Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells. J Viral Hepat 2004; 11: 394–403.

88 Beard MR, Abell G, Honda M et al. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology 1999; 30: 316–324.

89 Yi M, Bodola F, Lemon SM. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 2002; 304: 197–210.

90 Thomson M, Nascimbeni M, Gonzales S, Murthy KK, Rehermann B, Liang TJ. Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus. Gastroenterology 2001; 121: 1226–1233.

91 Heller T, Saito S, Auerbach J et al. An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A 2005; 102: 2579–2583.

92 Kato T, Matsumura T, Heller T et al. Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol 2007; 81: 4405–4411.

93 Blight KJ, Kolykhlov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972–1974.

94 Yanagi M, Purcell RH, Emerson SU, Bukh J. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 1999; 262: 250–263.